{"id":3119,"date":"2026-09-02T09:00:00","date_gmt":"2026-09-02T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3119"},"modified":"2026-09-14T20:29:32","modified_gmt":"2026-09-15T00:29:32","slug":"notch1-editing-enhances-car-t-expansion-in-models","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3119","title":{"rendered":"Notch1 Editing Enhances CAR T Expansion in Models"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Massachusetts General Hospital \/ Mass General Brigham<\/p>\n

Event Type<\/strong><\/p>\n

Preclinical Research Findings (Peer-Reviewed Publication)<\/p>\n

Modality<\/strong><\/p>\n

CRISPR\/Cas9 Gene-Edited CAR T-Cell Therapy<\/p>\n

Asset<\/strong><\/p>\n

Notch1 PEST-Domain-Edited CD19-4-1BB\u03b6 CAR T Cells<\/p>\n

Target<\/strong><\/p>\n

Endogenous Notch1 (CD19-directed CAR)<\/p>\n

Disease Area<\/strong><\/p>\n

B-Cell Acute Lymphoblastic Leukemia (preclinical model)<\/p>\n

Summary<\/h4>\n

A peer-reviewed Blood study used CRISPR\/Cas9 to delete the endogenous Notch1 PEST domain in CD19-4-1BB\u03b6 CAR T cells, extending native Notch1 signaling without constitutive overexpression. Edited cells expanded more strongly after activation, increased in-vitro cytotoxicity, and reduced tumor burden more effectively in B-ALL xenografts. The work identifies tunable native signaling as a potential route to persistence, but it remains preclinical and creates an important oncogenic-safety question because activating NOTCH1 lesions are established drivers of T-cell acute lymphoblastic leukemia.<\/p>\n

The investigators first found that both lentiviral overexpression of the Notch1 intracellular domain and complete Notch1 knockout impaired CAR T-cell activation and proliferation, indicating that balanced\u2014not maximal\u2014signaling is required. They then deleted the PEST degradation domain in endogenous Notch1. The resulting cells upregulated interferon-response and proliferation programs after CAR activation, expanded more than control cells, and showed greater killing of CD19-positive targets in vitro. In B-ALL xenografts, edited cells achieved greater tumor reduction and expansion than conventional CD19-4-1BB\u03b6 CAR T cells.<\/p>\n

The article was published online ahead of print on September 2, 2026. It is peer reviewed; no human, large-animal, manufacturing, clonal-expansion, insertion\/deletion-spectrum, off-target, or long-term tumorigenicity data were reported in the public abstract.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that precise editing of endogenous signal regulators can improve CAR T persistence while preserving physiologic control. Supporting evidence includes the failure of both signaling extremes, the transcriptional response, and concordant expansion and tumor-control findings. Contradicting evidence is that xenografts do not reproduce human immune pressure, exhaustion, manufacturing variability, or long-term clonal dynamics. A second interpretation is that the same lesion could exchange relapse risk for transformation or dysregulated immunity. NOTCH1 PEST-domain disruption is biologically linked to prolonged signaling and T-ALL, supporting that concern; the use of an endogenous, activation-dependent receptor rather than constitutive N1ICD argues against assuming equivalent risk. Neither interpretation is clinically established.<\/p>\n

Company and Product Background<\/h4>\n

The work was led by investigators at Massachusetts General Hospital and Mass General Brigham. CD19 CAR T therapy can induce deep remissions in B-cell malignancies, but relapse with retained CD19 is associated with inadequate expansion or persistence. Notch1 is a ligand-responsive receptor whose intracellular domain activates survival and inflammatory programs; its PEST domain promotes ubiquitination and degradation, limiting signal duration.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The translational bottleneck is safety, not conceptual novelty.<\/li>\n
  • Upgrades if:<\/strong> reproducible potency in patient-derived manufacturing runs, polyclonal editing, genome-wide off-target and translocation testing, normal-tissue and cytokine assessment, long-term large-animal studies, and a controllable safety switch are demonstrated.<\/li>\n
  • Downgrades if:<\/strong> unstable editing, loss of stem-like phenotype, tonic signaling, lineage skew, clonal dominance, or only modest benefit against antigen-variable tumors appear.<\/li>\n
  • Falsified if:<\/strong> durable control requires Notch1 activation levels that produce transformation, uncontrolled expansion, or unacceptable inflammatory toxicity.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a credible engineering insight rather than a treatment-ready platform. The elegant feature is the use of native regulation to avoid constitutive signaling; the critical risk is that the edited domain is itself a known oncogenic control point. Any development program should place long-horizon genotoxicity and clonality ahead of short xenograft efficacy.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 a novel CAR-engineering lever directly relevant to persistence and relapse. Importance:<\/strong> High \u2014 addresses a core limitation of CD19 CAR T therapy. Confidence:<\/strong> High on facts, low-moderate on interpretation \u2014 peer-reviewed online-first paper with concordant mechanistic and xenograft data, but no human, long-term safety, or scalable manufacturing evidence.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A peer-reviewed Blood study used CRISPR\/Cas9 to delete the endogenous Notch1 PEST domain in CD19-4-1BB\u03b6 CAR T cells, extending native Notch1 signaling without constitutive overexpression. Edited cells expanded more strongly after activation, increased in-vitro…<\/p>\n","protected":false},"author":1,"featured_media":3133,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[202,329,189],"class_list":["post-3119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-b-cell-acute-lymphoblastic-leukemia","tag-car-t-cell-therapy","tag-mass-general-brigham"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3119"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3119\/revisions"}],"predecessor-version":[{"id":3143,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3119\/revisions\/3143"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3133"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}